This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
| less than a minute read

Chinese authorities focus in on the collection of prescription and usage data in anti-corruption drive

As part of an anti-corruption campaign targeting the healthcare sector, the Chinese authorities’ latest measures seek to prohibit the improper collection of prescription and usage data by healthcare professionals (HCPs) and employees of healthcare companies. The regulations cover prescription and usage data in relation to pharmaceutical products, medical devices and medical consumables.

Our Asia-Pacific regulatory and investigations team cover the following issues in their latest alert:

  • an overview of  the regulations targeting HCPs;
  • an outline of the regulations targeting employees of companies in the healthcare sector; and
  • a useful explanation of what the regulations mean for you and how to deal with them.

Read the full alert here.

 

Tags

government investigations & white collar criminal defense, anti-corruption, bribery, china, fraud, healthcare, globalregulatoryenforcementlawblog, globalregulatoryenforcement